Customized Circulating Tumor DNA Testing for Cervical Cancer Recurrence Surveillance and Treatment Decisions
Not yet recruiting
- Conditions
- ImmunotherapyCervical CancerCtDNABiomarker
- First Posted Date
- 2024-10-21
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT06649838
Third-Generation Nanopore HPV Integration Site for Precise Prediction of Cervical Cancer Prognosis
Completed
- Conditions
- Cervical CancersHPV TestingNanopore SequencingHPV Integration Site DetectionRapid Diagnosis
- First Posted Date
- 2024-10-16
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT06644677
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Peking, Beijing, China
Moderated Hypofractionated Online Adaptive Radiotherapy in Cervical Cancer
Phase 3
Recruiting
- Conditions
- Cervical CancerAdaptive Radiotherapy
- First Posted Date
- 2024-10-15
- Last Posted Date
- 2025-03-18
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 440
- Registration Number
- NCT06641635
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, China
Diagnosis of Metastatic Tumors on 68Ga-FAPI-RGD PET-CT and Radioligand Therapy With 177Lu-FAPI-RGD
Early Phase 1
Recruiting
- Conditions
- FAP- Expressing Positive TumorsRGD- Expressing Positive Tumors
- Interventions
- Drug: 68Ga-FAPI-RGD for PET / CT scan and 177Lu-FAPI-RGD for therapy
- First Posted Date
- 2024-10-11
- Last Posted Date
- 2024-10-11
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 15
- Registration Number
- NCT06638034
- Locations
- 🇨🇳
Chinese Academy of Medical Science & Peking Union Medical College Hospital, Beijing, Beijing, China
177Lu-TATE-RGD in Patients With SSTR2 and Integrin αVβ3 Positive Tumors
Early Phase 1
Recruiting
- Conditions
- SSTR2 and Integrin αVβ3 Positive Tumors
- Interventions
- Drug: 177Lu-TATE-RGD
- First Posted Date
- 2024-10-09
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 10
- Registration Number
- NCT06632873
- Locations
- 🇨🇳
Chinese Academy of Medical Science & Peking Union Medical College Hospital, Beijing, Beijing, China
A Dual-targeting Tracer TATE-RGD for the Diagnosis of SSTR- and RGD- Positive Tumors
Early Phase 1
Recruiting
- Conditions
- Iodine-resistant Thyroid CancerMeningiomaNETs
- Interventions
- Drug: 18-FDG
- First Posted Date
- 2024-10-09
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT06632860
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
All-cause and Diseases-specific Mortality of High-risk HPV Infection
Not yet recruiting
- Conditions
- HPV Infection
- Interventions
- Other: Observation
- First Posted Date
- 2024-10-08
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 100000
- Registration Number
- NCT06631495
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, China
Daratumumab Combined with Venetoclax and Dexamethasone for Newly Diagnosed Light-Chain Amyloidosis with Translocation (11;14)
Phase 2
Recruiting
- Conditions
- Light Chain (AL) Amyloidosis
- Interventions
- First Posted Date
- 2024-10-08
- Last Posted Date
- 2025-01-22
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 36
- Registration Number
- NCT06629818
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, --- Select One ---, China
68Ga-NY104 PET/CT Guided Radiation Therapy in CcRCC.
Phase 2
Recruiting
- Conditions
- Clear Cell Renal Cell Carcinoma
- Interventions
- First Posted Date
- 2024-09-25
- Last Posted Date
- 2024-09-25
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT06613269
PEEP Titration and Lung Recruitment Potential Assessed by 3D EIT
Recruiting
- Conditions
- ARDSRespiratory Failure
- Interventions
- Procedure: lung recruitment potential assessed by 3D EITProcedure: PEEP titration by 3D eit
- First Posted Date
- 2024-09-13
- Last Posted Date
- 2024-09-13
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT06594601
- Locations
- 🇨🇳
Department of Critical Care Medicine, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences,, Beijing, Beijing, China
© Copyright 2025. All Rights Reserved by MedPath